{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:01:00Z","timestamp":1787896860709,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET\/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by <jats:sup>19<\/jats:sup>F magnetic resonance imaging (<jats:sup>19<\/jats:sup>F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results demonstrated high anti-MET\/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-022-01681-y","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:25:30Z","timestamp":1669919130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC"],"prefix":"10.1186","volume":"21","author":[{"given":"Yige","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoshuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"1681_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103\u20139.","journal-title":"Semin Cancer Biol"},{"key":"1681_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384.","journal-title":"Lung Cancer"},{"key":"1681_CR3","first-page":"6711","volume":"13","author":"GA Rodrigues","year":"1993","unstructured":"Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol. 1993;13:6711\u201322.","journal-title":"Mol Cell Biol"},{"key":"1681_CR4","first-page":"2019","volume":"9","author":"GA Rodrigues","year":"1994","unstructured":"Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene. 1994;9:2019\u201327.","journal-title":"Oncogene"},{"key":"1681_CR5","doi-asserted-by":"publisher","first-page":"14417","DOI":"10.1073\/pnas.95.24.14417","volume":"95","author":"M Jeffers","year":"1998","unstructured":"Jeffers M, Fiscella, M, Webb C.P., Anver M, Koochekpour S, Vande Woude G.F. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A. 1998;95:14417\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1681_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89\u2013103.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102173","volume":"95","author":"YL Wu","year":"2021","unstructured":"Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies. Cancer Treat Rev. 2021;95: 102173.","journal-title":"Cancer Treat Rev"},{"key":"1681_CR8","unstructured":"FDA approves capmatinib for metastatic non-small cell lung cancer. https:\/\/www.fda.gov 2022 August 10];"},{"key":"1681_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.biomaterials.2017.09.027","volume":"148","author":"KH Bae","year":"2017","unstructured":"Bae KH, Tan S, Yamashita A, Ang WX, Gao SJ, Wang S, et al. Hyaluronic acid-green tea catechin micellar nanocomplexes: fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity. Biomaterials. 2017;148:41\u201353.","journal-title":"Biomaterials"},{"key":"1681_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-Mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944\u201357.","journal-title":"N Engl J Med"},{"key":"1681_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1007\/s10439-009-9643-z","volume":"37","author":"MM Kaneda","year":"2009","unstructured":"Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng. 2009;37:1922\u201333.","journal-title":"Ann Biomed Eng"},{"key":"1681_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nbm.3059","volume":"27","author":"C Jacoby","year":"2014","unstructured":"Jacoby C, Temme S, Mayenfels F, Benoit N, Krafft MP, Schubert R, et al. Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half-lives and sensitivity. NMR Biomed. 2014;27:261\u201371.","journal-title":"NMR Biomed"},{"key":"1681_CR14","first-page":"515","volume":"2","author":"TD Tran","year":"2007","unstructured":"Tran TD, Caruthers SD, Hughes M, Marsh JN, Cyrus T, Winter PM, et al. Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine. 2007;2:515\u201326.","journal-title":"Int J Nanomedicine"},{"key":"1681_CR15","first-page":"475","volume":"1","author":"AH Schmieder","year":"2015","unstructured":"Schmieder AH, Caruthers SD, Keupp J, Wickline SA, Lanza GM. Recent advances in (19)fluorine magnetic resonance imaging with perfluorocarbon emulsions. Engineering (Beijing). 2015;1:475\u201389.","journal-title":"Engineering (Beijing)"},{"key":"1681_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/1061186X.2021.1999963","volume":"30","author":"Y Du","year":"2022","unstructured":"Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target. 2022;30:287\u2013301.","journal-title":"J Drug Target"},{"key":"1681_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10456-010-9166-0","volume":"13","author":"GM Lanza","year":"2010","unstructured":"Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis. 2010;13:189\u2013202.","journal-title":"Angiogenesis"},{"key":"1681_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.chest.2019.11.036","volume":"157","author":"H Wang","year":"2020","unstructured":"Wang H, Wu L, Sun X. Intratracheal delivery of nano- and microparticles and hyperpolarized gases: a promising strategy for the imaging and treatment of respiratory disease. Chest. 2020;157:1579\u201390.","journal-title":"Chest"},{"key":"1681_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.biomaterials.2019.01.002","volume":"197","author":"J Zhou","year":"2019","unstructured":"Zhou J, Xue C, Hou Y, Li M, Hu Y, Chen Q, et al. Oxygenated theranostic nanoplatforms with intracellular agglomeration behavior for improving the treatment efficacy of hypoxic tumors. Biomaterials. 2019;197:129\u201345.","journal-title":"Biomaterials"},{"key":"1681_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.7150\/thno.21466","volume":"8","author":"L Wu","year":"2018","unstructured":"Wu L, Wen X, Wang X, Wang C, Sun X, Wang K, et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging. Theranostics. 2018;8:563\u201374.","journal-title":"Theranostics"},{"key":"1681_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.athoracsur.2014.01.048","volume":"97","author":"T Nakajima","year":"2014","unstructured":"Nakajima T, Anayama T, Matsuda Y, Hwang DM, McVeigh PZ, Wilson BC, et al. Orthotopic lung cancer murine model by nonoperative transbronchial approach. Ann Thorac Surg. 2014;97:1771\u20135.","journal-title":"Ann Thorac Surg"},{"key":"1681_CR22","doi-asserted-by":"crossref","unstructured":"Yang, J., Y. Li, J. Sun, H. Zou, Y. Sun, J. Luo, et al., An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration. ACS Nano. 2022.","DOI":"10.1021\/acsnano.2c04159"},{"key":"1681_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med. 2021;27:1250\u201361.","journal-title":"Nat Med"},{"key":"1681_CR24","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","volume":"11","author":"VS Pelly","year":"2021","unstructured":"Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 2021;11:2602\u201319.","journal-title":"Cancer Discov"},{"key":"1681_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.molmed.2005.04.005","volume":"11","author":"S Corso","year":"2005","unstructured":"Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005;11:284\u201392.","journal-title":"Trends Mol Med"},{"key":"1681_CR26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2017.04.031","volume":"12","author":"GD Lee","year":"2017","unstructured":"Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, et al. MET Exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values. J Thorac Oncol. 2017;12:1233\u201346.","journal-title":"J Thorac Oncol"},{"key":"1681_CR27","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441\u201354.","journal-title":"J Natl Cancer Inst"},{"key":"1681_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nrc1886","volume":"6","author":"P Mehlen","year":"2006","unstructured":"Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449\u201358.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"1681_CR30","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310\u20136.","journal-title":"Clin Cancer Res"},{"key":"1681_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrc2289","volume":"8","author":"K Brindle","year":"2008","unstructured":"Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008;8:94\u2013107.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR32","doi-asserted-by":"publisher","first-page":"H217","DOI":"10.1002\/adma.201102313","volume":"23","author":"FM Kievit","year":"2011","unstructured":"Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23:H217\u201347.","journal-title":"Adv Mater"},{"key":"1681_CR33","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","volume":"27","author":"F Fontana","year":"2021","unstructured":"Fontana F, Scott MJ, Allen JS, Yang X, Cui G, Pan D, et al. VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival. Clin Cancer Res. 2021;27:1974\u201386.","journal-title":"Clin Cancer Res"},{"key":"1681_CR34","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1096\/fj.08-112060","volume":"22","author":"AH Schmieder","year":"2008","unstructured":"Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. Faseb j. 2008;22:4179\u201389.","journal-title":"Faseb j"},{"key":"1681_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-012-9310-0","volume":"16","author":"C Giraudeau","year":"2013","unstructured":"Giraudeau C, Geffroy F, M\u00e9riaux S, Boumezbeur F, Robert P, Port M, et al. 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles. Angiogenesis. 2013;16:171\u20139.","journal-title":"Angiogenesis"},{"key":"1681_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1021\/cr500286d","volume":"115","author":"I Tirotta","year":"2015","unstructured":"Tirotta I, Dichiarante V, Pigliacelli C, Cavallo G, Terraneo G, Bombelli FB, et al. (19)F magnetic resonance imaging (MRI): from design of materials to clinical applications. Chem Rev. 2015;115:1106\u201329.","journal-title":"Chem Rev"},{"key":"1681_CR37","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1161\/01.CIR.0000044020.27990.32","volume":"106","author":"GM Lanza","year":"2002","unstructured":"Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation. 2002;106:2842\u20137.","journal-title":"Circulation"},{"key":"1681_CR38","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1124\/dmd.119.090324","volume":"48","author":"U Glaenzel","year":"2020","unstructured":"Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, et al. Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metab Dispos. 2020;48:873\u201385.","journal-title":"Drug Metab Dispos"},{"issue":"506","key":"1681_CR39","doi-asserted-by":"publisher","first-page":"eaaw7736","DOI":"10.1126\/scitranslmed.aaw7736","volume":"11","author":"T Binderup","year":"2019","unstructured":"Binderup T, Duivenvoorden R, Fay F, van Leent MMT, Malkus J, Baxter S, et al. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci Transl Med. 2019;11(506):eaaw7736.","journal-title":"Sci Transl Med"},{"key":"1681_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1081\/PDT-100101357","volume":"4","author":"YF Maa","year":"1999","unstructured":"Maa YF, Hsu CC. Performance of sonication and microfluidization for liquid-liquid emulsification. Pharm Dev Technol. 1999;4:233\u201340.","journal-title":"Pharm Dev Technol"},{"key":"1681_CR41","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/jbm.a.34850","volume":"102","author":"YC Chen","year":"2014","unstructured":"Chen YC, Lo CL, Hsiue GH. Multifunctional nanomicellar systems for delivering anticancer drugs. J Biomed Mater Res A. 2014;102:2024\u201338.","journal-title":"J Biomed Mater Res A"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01681-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01681-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01681-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:26:30Z","timestamp":1669919190000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01681-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01681-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mice handling was in terms of the procedures approved by the Harbin Medical University Institutional Animal Care and Use Committee and complied with relevant ethical standards. All human specimens related experiments were in accordance with the related ethical regulations of the ethics committee of the Fourth Affiliated Hospital of Harbin Medical University (2020-SCILLSC-19). All patients signed informed consent for usage of medical history data and biospecimens before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competitive interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}